BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.
Frequently asked questions
What sector does BB Biotech AG (BBZA) operate in?
BB Biotech AG belongs to the Healthcare sector and operates in the Biotechnology industry.
What is BB Biotech AG (BBZA) current stock price?
As of the latest data, BB Biotech AG stock price is €53.50, with a previous close of €53.00. BB Biotech AG gained €0.50 in the last trading session, representing a 0.94% increase.
What is BB Biotech AG (BBZA) current market capitalization?
BB Biotech AG market cap is approximately 2.95 billion.
What is BB Biotech AG (BBZA) Earnings Per Share (EPS)?
The trailing EPS is -€8.52, and the forward EPS is €2.19.
What is BB Biotech AG (BBZA) EBITDA?
BB Biotech AG EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 486.54 million.
Does BB Biotech AG (BBZA) pay dividends?
Yes. BB Biotech AG pays annual dividends with an annualized yield of 4.91% and an estimated annual payout of €2.43 per share.
When is the next ex-dividend date for BB Biotech AG (BBZA)?
The next ex-dividend date is scheduled for March 23, 2027.
When is BB Biotech AG (BBZA) next earnings report?
BB Biotech AG is expected to release its next earnings report on September 30, 2026.
What is BB Biotech AG (BBZA) beta (volatility) score?
BB Biotech AG has a beta of 0.671, indicating lower volatility than the overall market.
